A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
about
Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient dataIron deficiency in gastrointestinal oncologyActivities of erythropoietin on tumors: an immunological perspective.Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in IndiaRecombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitroImpact of preoperative anemia on relapse and survival in breast cancer patients.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling studyCost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United StatesAssociation of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based StudyThe Use of Epoetin-α in Revision Knee Arthroplasty.Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients.A case-control study of prevalence of anemia among patients with type 2 diabetesPrevalence and management of anaemia in patients with non-myeloid cancer undergoing systemic therapy: a Spanish survey.Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.Recombinant human epoetin beta in the treatment of chemotherapy-related anemia.The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.Update on the therapy for myelodysplastic syndrome.Improving the evidence base for transfusion medicine: the work of the UK systematic review initiative.Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events.A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.Diagnosis and management of anaemia of chronic disease: current status.The Use of Preoperative Epoetin-α in Revision Hip Arthroplasty.Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis.Emerging drugs for treatment of anemia of chronic kidney disease.Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.Fighting insomnia and battling lethargy: the yin and yang of palliative care.The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.Single versus double-unit transfusion policy in hematology.Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy.Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008.
P2860
Q24240202-3706F540-62FD-4142-B1BB-2E4D87C4BD5BQ27023196-05EF57C5-B174-41DD-A4E1-D51FB581B760Q33344041-BED97127-3CDD-4956-8BAE-45EFF38E22C3Q33698956-249BCF6A-B302-49CF-8478-77AB35C1B03AQ34107767-3BD2B2B4-14D9-4E9B-8DDE-10D34FB8E8FDQ34565736-188E9EB8-5D47-4687-9497-0D9186A204BAQ34635638-C663376F-30F6-452B-B3B7-BDC53FF17E96Q34690368-21010E88-AD30-43C7-B3E5-FF7B8C53E0BDQ35619161-FC5050B4-516F-4879-9263-370ED43F100DQ35751128-C26F0EFD-1719-45B9-A832-913D13DB5F53Q36091004-4D5E792F-C031-4969-9AFE-C8C54C500F19Q36755204-025D0E28-B447-45D8-976E-BD22B2B97A9EQ36866979-D9ACB2A4-3DAE-4492-AEF8-B13DDC4FAA07Q36875147-2643BBC4-27B0-4C9F-9333-6393DF49A920Q37058440-A597C3D1-2EB3-402B-95EC-7F1E736AFAD3Q37224299-EAF0F526-8C70-4AB7-A009-93EB7B93D38DQ37230276-B10FEDEB-D501-4E74-A46A-77862931F37CQ37260416-8AD2D0FC-7DCA-42E8-85A4-D3F7BA80E2EDQ37286544-A5C13DCF-A0F6-4E39-ACA7-510D57F4F820Q37385953-DE895A68-CCDC-47A1-9185-8C106D7BF94CQ37423362-3F455BBD-108D-4F5A-8CEA-A0A8BDF63674Q37481924-F652FB33-E897-4840-A2FE-3773B8E8B6AEQ37626692-93C15423-0F19-4128-9CD3-3529994A1C44Q37702223-5D03AFFE-F715-45E3-B54B-42101C56F4EAQ37766575-C0D26C75-55F8-4F67-B5FD-A3F1C409727FQ37880158-11B102B1-45BF-411C-97AE-B90CCBBDFB75Q38013113-824E3A6A-DFEF-426A-9D8C-74866E9F5FE6Q38130141-18806361-D434-4C51-9D90-08F894573FAEQ38137205-8290309B-3F73-4A01-9B8B-0132D5BEFA15Q38152967-2AAE8838-FBDD-42FD-83E9-5AE03F17FB52Q38188834-39526DD5-97C7-4FA1-8731-E0DF281C9E2EQ38740871-6C814D88-7672-4DCD-B0E0-DED5473D70C0Q39478177-16C6B9D1-6F43-4995-8865-D0C77D73E9A9Q43224599-5CC2E3B7-81B0-4691-8473-0A2A2D932A44Q44329336-DF398BAA-4DBE-4B6A-9E9E-2BE223A45301Q44420464-7880B13C-5407-4A98-A7D6-FB99563F143DQ44680290-0D565772-F11A-40EA-9519-A137E29D9834Q44921002-F3491FF1-1CA7-4BCF-91B2-FCD3E54A676BQ45326017-1ABC3B77-6EB6-462C-97E1-D5E5C46E8C56Q45330459-FA1A234E-AA7A-4B53-A1E2-6CA0171BF89C
P2860
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
A systematic review and econom ...... ributable to cancer treatment.
@ast
A systematic review and econom ...... ributable to cancer treatment.
@en
type
label
A systematic review and econom ...... ributable to cancer treatment.
@ast
A systematic review and econom ...... ributable to cancer treatment.
@en
prefLabel
A systematic review and econom ...... ributable to cancer treatment.
@ast
A systematic review and econom ...... ributable to cancer treatment.
@en
P2093
P356
P1476
A systematic review and econom ...... ributable to cancer treatment.
@en
P2093
J Sandercock
S Brunskill
S Stanworth
P304
1-202, iii-iv
P356
10.3310/HTA11130
P577
2007-04-01T00:00:00Z